462 related articles for article (PubMed ID: 24166615)
1. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood.
Belzil VV; Bauer PO; Prudencio M; Gendron TF; Stetler CT; Yan IK; Pregent L; Daughrity L; Baker MC; Rademakers R; Boylan K; Patel TC; Dickson DW; Petrucelli L
Acta Neuropathol; 2013 Dec; 126(6):895-905. PubMed ID: 24166615
[TBL] [Abstract][Full Text] [Related]
2. Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients.
Belzil VV; Bauer PO; Gendron TF; Murray ME; Dickson D; Petrucelli L
Brain Res; 2014 Oct; 1584():15-21. PubMed ID: 24530272
[TBL] [Abstract][Full Text] [Related]
3. Methylation of C9orf72 expansion reduces RNA foci formation and dipeptide-repeat proteins expression in cells.
Bauer PO
Neurosci Lett; 2016 Jan; 612():204-209. PubMed ID: 26690922
[TBL] [Abstract][Full Text] [Related]
4. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS.
Gendron TF; Bieniek KF; Zhang YJ; Jansen-West K; Ash PE; Caulfield T; Daughrity L; Dunmore JH; Castanedes-Casey M; Chew J; Cosio DM; van Blitterswijk M; Lee WC; Rademakers R; Boylan KB; Dickson DW; Petrucelli L
Acta Neuropathol; 2013 Dec; 126(6):829-44. PubMed ID: 24129584
[TBL] [Abstract][Full Text] [Related]
5. Making sense of the antisense transcripts in C9FTD/ALS.
Todd PK
Acta Neuropathol; 2013 Dec; 126(6):785-7. PubMed ID: 24178412
[No Abstract] [Full Text] [Related]
6. Molecular Mechanisms of Neurodegeneration Related to
Babić Leko M; Župunski V; Kirincich J; Smilović D; Hortobágyi T; Hof PR; Šimić G
Behav Neurol; 2019; 2019():2909168. PubMed ID: 30774737
[TBL] [Abstract][Full Text] [Related]
7. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72.
Murray ME; DeJesus-Hernandez M; Rutherford NJ; Baker M; Duara R; Graff-Radford NR; Wszolek ZK; Ferman TJ; Josephs KA; Boylan KB; Rademakers R; Dickson DW
Acta Neuropathol; 2011 Dec; 122(6):673-90. PubMed ID: 22083254
[TBL] [Abstract][Full Text] [Related]
8. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study.
Gijselinck I; Van Langenhove T; van der Zee J; Sleegers K; Philtjens S; Kleinberger G; Janssens J; Bettens K; Van Cauwenberghe C; Pereson S; Engelborghs S; Sieben A; De Jonghe P; Vandenberghe R; Santens P; De Bleecker J; Maes G; Bäumer V; Dillen L; Joris G; Cuijt I; Corsmit E; Elinck E; Van Dongen J; Vermeulen S; Van den Broeck M; Vaerenberg C; Mattheijssens M; Peeters K; Robberecht W; Cras P; Martin JJ; De Deyn PP; Cruts M; Van Broeckhoven C
Lancet Neurol; 2012 Jan; 11(1):54-65. PubMed ID: 22154785
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a family with c9FTD/ALS associated with the GGGGCC repeat expansion in C9ORF72.
Savica R; Adeli A; Vemuri P; Knopman DS; Dejesus-Hernandez M; Rademakers R; Fields JA; Whitwell J; Jack CR; Lowe V; Petersen RC; Boeve BF
Arch Neurol; 2012 Sep; 69(9):1164-9. PubMed ID: 22637471
[TBL] [Abstract][Full Text] [Related]
10. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS.
Ash PE; Bieniek KF; Gendron TF; Caulfield T; Lin WL; Dejesus-Hernandez M; van Blitterswijk MM; Jansen-West K; Paul JW; Rademakers R; Boylan KB; Dickson DW; Petrucelli L
Neuron; 2013 Feb; 77(4):639-46. PubMed ID: 23415312
[TBL] [Abstract][Full Text] [Related]
11. The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients.
Xi Z; Zhang M; Bruni AC; Maletta RG; Colao R; Fratta P; Polke JM; Sweeney MG; Mudanohwo E; Nacmias B; Sorbi S; Tartaglia MC; Rainero I; Rubino E; Pinessi L; Galimberti D; Surace EI; McGoldrick P; McKeever P; Moreno D; Sato C; Liang Y; Keith J; Zinman L; Robertson J; Rogaeva E
Acta Neuropathol; 2015 May; 129(5):715-27. PubMed ID: 25716178
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier.
Russ J; Liu EY; Wu K; Neal D; Suh E; Irwin DJ; McMillan CT; Harms MB; Cairns NJ; Wood EM; Xie SX; Elman L; McCluskey L; Grossman M; Van Deerlin VM; Lee EB
Acta Neuropathol; 2015 Jan; 129(1):39-52. PubMed ID: 25388784
[TBL] [Abstract][Full Text] [Related]
13. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress.
Zhang YJ; Jansen-West K; Xu YF; Gendron TF; Bieniek KF; Lin WL; Sasaguri H; Caulfield T; Hubbard J; Daughrity L; Chew J; Belzil VV; Prudencio M; Stankowski JN; Castanedes-Casey M; Whitelaw E; Ash PE; DeTure M; Rademakers R; Boylan KB; Dickson DW; Petrucelli L
Acta Neuropathol; 2014 Oct; 128(4):505-24. PubMed ID: 25173361
[TBL] [Abstract][Full Text] [Related]
14. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter.
Gijselinck I; Van Mossevelde S; van der Zee J; Sieben A; Engelborghs S; De Bleecker J; Ivanoiu A; Deryck O; Edbauer D; Zhang M; Heeman B; Bäumer V; Van den Broeck M; Mattheijssens M; Peeters K; Rogaeva E; De Jonghe P; Cras P; Martin JJ; de Deyn PP; Cruts M; Van Broeckhoven C
Mol Psychiatry; 2016 Aug; 21(8):1112-24. PubMed ID: 26481318
[TBL] [Abstract][Full Text] [Related]
15. c9RAN translation: a potential therapeutic target for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia.
Gendron TF; Cosio DM; Petrucelli L
Expert Opin Ther Targets; 2013 Sep; 17(9):991-5. PubMed ID: 23844663
[TBL] [Abstract][Full Text] [Related]
16. Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72.
Konno T; Shiga A; Tsujino A; Sugai A; Kato T; Kanai K; Yokoseki A; Eguchi H; Kuwabara S; Nishizawa M; Takahashi H; Onodera O
J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):398-401. PubMed ID: 23012445
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic determinants and mechanisms of ALS/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene.
Wen X; Westergard T; Pasinelli P; Trotti D
Neurosci Lett; 2017 Jan; 636():16-26. PubMed ID: 27619540
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS.
Yamakawa M; Ito D; Honda T; Kubo K; Noda M; Nakajima K; Suzuki N
Hum Mol Genet; 2015 Mar; 24(6):1630-45. PubMed ID: 25398948
[TBL] [Abstract][Full Text] [Related]
19. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.
Lagier-Tourenne C; Baughn M; Rigo F; Sun S; Liu P; Li HR; Jiang J; Watt AT; Chun S; Katz M; Qiu J; Sun Y; Ling SC; Zhu Q; Polymenidou M; Drenner K; Artates JW; McAlonis-Downes M; Markmiller S; Hutt KR; Pizzo DP; Cady J; Harms MB; Baloh RH; Vandenberg SR; Yeo GW; Fu XD; Bennett CF; Cleveland DW; Ravits J
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):E4530-9. PubMed ID: 24170860
[TBL] [Abstract][Full Text] [Related]
20. Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration.
Suh E; Lee EB; Neal D; Wood EM; Toledo JB; Rennert L; Irwin DJ; McMillan CT; Krock B; Elman LB; McCluskey LF; Grossman M; Xie SX; Trojanowski JQ; Van Deerlin VM
Acta Neuropathol; 2015 Sep; 130(3):363-72. PubMed ID: 26022924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
